LDL-binding IL-10 reduces vascular inflammation in atherosclerotic mice

Area of Science:

• Immunology
• Cardiovascular Biology
• Biotechnology

Background:

• Atherosclerosis is a chronic inflammatory disease driven by low-density lipoprotein (LDL) accumulation.
• Elevated anti-inflammatory cytokine IL-10 correlates with reduced atherosclerotic plaque burden.
• Existing cytokine therapies face challenges like rapid clearance and off-target effects.

Purpose of the Study:

• To engineer a targeted delivery system for IL-10 to atherosclerotic plaques.
• To overcome limitations of traditional cytokine therapies in treating atherosclerosis.
• To evaluate the therapeutic potential of LDL-targeted IL-10 in preclinical models.

Main Methods:

• Constructed Fab-IL-10 fusion proteins by linking IL-10 to LDL-binding antibody fragments (Fabs).
• Administered Fab-IL-10 constructs systemically in atherosclerosis mouse models.
• Assessed plaque burden, immune cell infiltration, and macrophage activation markers.

Main Results:

• Fab-IL-10 constructs successfully bound circulating LDL and localized to atherosclerotic plaques.
• The 2D03-IL-10 construct markedly reduced aortic immune cell infiltration in mouse models.
• Targeted 2D03-IL-10 therapy decreased pro-inflammatory markers and associated with foamy macrophages.

Conclusions:

• LDL-targeted IL-10, specifically 2D03-IL-10, demonstrates potent anti-atherosclerotic effects.
• This modular protein engineering approach shows promise for targeted anti-inflammatory therapies.
• The technology may be adaptable for delivering various protein therapeutics to specific disease sites.